USZ BioResource COVID-19

Official Title

Development of a SARS-CoV-2 Research Biobank and Databank

Brief Summary

Mono-centric. Blood sampling for biobank development, including linkage to patient data (resource for research on COVID19).

Status

Terminated

Conditions

COVID19

Interventions

Other: blood sampling for biobank

blood sampling for biobank

Eligibility Criteria

Inclusion Criteria:

- m/f age > 18 years

- SARS-CoV-2 infektion (according to WHO guideline)

- hospitalisation, general ward

- acceptable language knowledge

- voluntary IFC and biobank appendix

Exclusion Criteria:

- contra indication for blood sampling

Eligibility Gender

All

Eligibility Age

Minimum: 18 Years ~ Maximum: N/A

Countries

Switzerland

Locations

University Hospital Zurich, Clinical Trials Center
Zurich, Switzerland

Investigators

Regina Grossmann, Dr med, Study Director
Head of Clinical Trials Center University Hospital Zurich

NCT Number

NCT04414657

MeSH Terms

COVID-19

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

Regina Grossmann

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA